<DOC>
	<DOCNO>NCT02688101</DOCNO>
	<brief_summary>Multicenter , open-label , dose-escalation pharmacokinetic study .</brief_summary>
	<brief_title>Dose-finding Pharmacokinetic Study DpC , Administered Orally Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>Multicenter , open-label , phase 1 study DpC administer orally patient advance solid tumor . The study conduct two part . In first phase successive cohort patient ( 3+3 ) receive escalate dos DpC maximum tolerate dose ( MTD ) reach . MTD base tolerability observe first 28 day treatment . The second part study involve treatment expansion cohort ( 10-15 patient ) specific indication confirm tolerability treatment recommend phase 2 dose schedule evaluate evidence anti-tumor activity .</detailed_description>
	<criteria>Signed informed consent prior initiation studyspecific procedure ; Histologically cytologically confirm diagnosis advance metastatic solid tumor standard therapy either exist proven ineffective , intolerable , unacceptable patient ; At least one measurable lesion define RECIST v1.1 , except patient castrate resistant prostate cancer , may enrol objective evidence disease per PCWG2 criterion , patient ovarian cancer may enrol without measurable disease evaluable CA125 per GCIC criterion ; life expectancy least 3 month ; ECOG performance status 01 ; Adequate bone marrow reserve , cardiac , renal liver function , define absolute neutrophil count least 1.5 x 10 ( 9 ) /L ; platelet count least 100 x 10 ( 9 ) /L ; hemoglobin least 9 g/dL ; ferritin least 50 ug/L ; ECHO show ejection fraction least 50 % evidence cardiac dysfunction ; creatinine clearance &gt; 50 mL/min ( Cockcroft &amp; Gault formula ) ; AST/ALT 3 x ULN ( 5 x ULN liver bone involvement ) ; serum albumin least 28 g/L ; INR 1.5 x ULN ; At least 3 week since chemotherapy , immunotherapy , hormone therapy , r anticancer therapy surgical intervention least 3 halflie monoclonal antibody ; Patients castrateresistant prostate cancer must maintain ongoing androgen deprivation therapy provide serum testosterone &lt; 50 mg/dL ; Patients receive bisphosphonate denosumab therapy must stable dos least 4 week initiate study treatment . Inability swallow oral medication presence GI disorder deem jeopardize intestinal absorption DpC ; Persistent grade &gt; 1 clinically significant toxicity relate prior anticancer treatment ( except alopecia ) ; Known primary CNS malignancy CNS involvement ( except brain mets treat stable patient steroid ) ; History prior concomitant malignancy ( fully excise nonmelanoma skin cancer , cure situ cervical carcinoma , early stage bladder cancer DCIS breast ) within 3 year study entry ; History atrial fibrillation evidence atrial enlargement baseline ECHO ; History hemoglobinopathy ; Current use iron chelation therapy ; Other serious illness medial condition ; Participation another clinical trial treatment investigational drug within 30 day prior study entry ; Current use anticoagulant therapeutic level ; Pregnant breastfeed patient men woman childbearing potential use effective contraception study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>